The stock 4564.T stock (OncoTherapy Science, Inc., JPX) traded as one of Japan’s most active after-hours issues on 06 Mar 2026, closing at JPY 20.00 on heavy turnover. Volume reached 48,921,400.00 shares versus an average of 42,866,803.00, marking a relative volume of 1.14 and signalling focused interest ahead of a May earnings event. Market moves reflect clinical progress, short-term technical weakness and a narrow market cap of JPY 6,872,871,980.00, creating a high-volatility setup for traders and longer-term watchers.

Trading snapshot and liquidity

OncoTherapy Science (4564.T) finished after hours at JPY 20.00 with an intraday high of JPY 21.00 and low of JPY 20.00, driven by 48,921,400.00 shares traded. Average volume is 42,866,803.00, so today’s activity is materially above normal and places the stock on the most-active lists on the JPX market in Japan.

Fundamentals and company rating

Earnings remain negative with EPS -2.83 and reported PE at -7.07, while Price to Book is 3.37 and Price to Sales is 8.76, reflecting biotech-stage valuation. The independent company rating dated 05 Mar 2026 lists a C (Sell) view; this contrasts with strong liquidity and a current ratio of 8.51, signalling a healthy cash buffer despite operating losses.

Meyka AI grade and model forecast

Meyka AI rates 4564.T with a score out of 100: 69.32 / B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month value of JPY 17.31, implying a -13.45% downside from the current JPY 20.00, and model caveats stress clinical and binary catalyst risk. Forecasts are model-based projections and not guarantees.

Technical picture and volatility signals

Momentum indicators show pressure: RSI 40.88, MACD histogram -0.02, and ATR 1.39, suggesting limited trend strength and above-average intraday swings; Bollinger Bands run 19.50–21.50. On balance volume is negative while MFI is high at 75.86, which can indicate crowd interest with buying exhaustion. Price sits below the 200-day average of JPY 23.93 but near the 50-day average of JPY 20.90, a mixed short-term technical setup.

Pipeline catalysts, risks and sector context

OncoTherapy’s clinical pipeline (S-588410 Phase III, OTS167, OTSA101 and KHK6640 early trials) drives event risk and potential re-rating; upcoming FY earnings on 07 May 2026 and trial readouts are key catalysts. The Healthcare sector (Japan) carries a 1-year performance of 27.03% and higher PE norms (~24.15), which makes OncoTherapy’s biotech valuation sensitive to clinical news and funding moves.

Valuation and practical price targets

Given current fundamentals and volatility, practical near-term targets are: a conservative JPY 15.60 (quarterly model), base JPY 17.31 (Meyka yearly), and optimistic JPY 21.00 (event-driven upside). At JPY 17.31 the implied downside is -13.45%; at JPY 21.00 the implied upside is +5.00%. These price targets reflect clinical binary risk, cash runway, and sector re-rating sensitivity.

Final Thoughts

Key takeaways for 4564.T stock: the after-hours most-active status on 06 Mar 2026 highlights heightened trader attention with JPY 20.00 price and 48,921,400.00 shares traded. Fundamentals show operating losses (EPS -2.83) and a negative PE (-7.07), but a strong short-term liquidity profile with current ratio 8.51. Meyka AI assigns a 69.32 / B (HOLD) grade and projects a 12-month model price of JPY 17.31, implying -13.45% from current levels; forecasts are model-based projections and not guarantees. Near-term investors should weigh the May earnings and clinical milestones that can rapidly change valuation. For traders, high volume and ATR 1.39 support tactical entries with tight risk controls. For long-term investors, the balance between pipeline upside and recurring losses points to event-driven allocation only. For the latest filings and corporate releases visit OncoTherapy Science official site and check JPX market updates at Japan Exchange Group. Meyka AI provides this as an AI-powered market analysis platform and not as financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.